TNSN08196A1 - Derives de pyrazine - Google Patents

Derives de pyrazine

Info

Publication number
TNSN08196A1
TNSN08196A1 TNP2008000196A TNSN08196A TNSN08196A1 TN SN08196 A1 TNSN08196 A1 TN SN08196A1 TN P2008000196 A TNP2008000196 A TN P2008000196A TN SN08196 A TNSN08196 A TN SN08196A TN SN08196 A1 TNSN08196 A1 TN SN08196A1
Authority
TN
Tunisia
Prior art keywords
des
composés
préparer
pour les
les
Prior art date
Application number
TNP2008000196A
Other languages
English (en)
Inventor
Karl Richard Gibson
Cedric Poinsard
Melanie Susanne Glossop
Stephen Martin Denton
Mark Ian Kemp
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of TNSN08196A1 publication Critical patent/TNSN08196A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La présente invention concerne des composés de formule (I), des sels et solvates de ceux-ci, acceptables d'un point de vue pharmaceutique, des procédés pour les préparer, des produits intermédiaires utilisés pour les préparer, des compositions contenant ces composés, ainsi que les utilisations de tels composés dans le traitement de la douleur.
TNP2008000196A 2005-11-04 2008-05-02 Derives de pyrazine TNSN08196A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73366205P 2005-11-04 2005-11-04
PCT/IB2006/003055 WO2007052123A2 (fr) 2005-11-04 2006-10-23 Derives de pyrazine

Publications (1)

Publication Number Publication Date
TNSN08196A1 true TNSN08196A1 (fr) 2009-10-30

Family

ID=37890558

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000196A TNSN08196A1 (fr) 2005-11-04 2008-05-02 Derives de pyrazine

Country Status (27)

Country Link
US (1) US7572797B2 (fr)
EP (1) EP1945630B1 (fr)
JP (1) JP2009514937A (fr)
KR (1) KR20080066073A (fr)
CN (1) CN101356169A (fr)
AP (1) AP2008004468A0 (fr)
AR (1) AR057855A1 (fr)
AT (1) ATE525372T1 (fr)
AU (1) AU2006310215A1 (fr)
BR (1) BRPI0618129A2 (fr)
CA (1) CA2624621C (fr)
CR (1) CR9954A (fr)
DO (1) DOP2006000243A (fr)
EA (1) EA200801011A1 (fr)
EC (1) ECSP088412A (fr)
ES (1) ES2371932T3 (fr)
GT (1) GT200600475A (fr)
IL (1) IL191059A0 (fr)
MA (1) MA29926B1 (fr)
NL (1) NL2000284C2 (fr)
NO (1) NO20082496L (fr)
PE (1) PE20070715A1 (fr)
TN (1) TNSN08196A1 (fr)
TW (1) TW200804353A (fr)
UY (1) UY29893A1 (fr)
WO (1) WO2007052123A2 (fr)
ZA (1) ZA200803671B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
EP1741708A1 (fr) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Amides heterocycliques substitués contenant un linker cyclique ou insaturé, et leur utilisation comme agent pharmaceutique
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US20100227872A1 (en) * 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
ES2398606T3 (es) 2007-05-03 2013-03-20 Pfizer Limited Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio
US8614255B2 (en) * 2007-08-21 2013-12-24 Civitas Therapeutics, Inc. Pulmonary pharmaceutical formulations
AU2008334629B2 (en) 2007-12-10 2012-04-12 Novartis Ag Organic compounds
RU2010137862A (ru) 2008-02-13 2012-03-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Производное бициклоамина
EA019819B1 (ru) 2008-05-23 2014-06-30 ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9856240B2 (en) * 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
TWI577677B (zh) * 2012-04-25 2017-04-11 拉夸里亞創藥股份有限公司 作爲ｔｔｘ－ｓ阻斷劑之吡咯並吡啶酮衍生物
TWI644899B (zh) * 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
US9079866B2 (en) 2013-02-04 2015-07-14 Janssen Pharmaceutica Nv Flap modulators
EP3193603A4 (fr) * 2014-09-10 2018-02-28 Epizyme, Inc. Composés carboxamides isoxazoles
US11311535B2 (en) 2015-02-27 2022-04-26 Calcimedica, Inc. Pancreatitis treatment
CA2995094A1 (fr) * 2015-08-07 2017-02-16 Calcimedica, Inc. Utilisation d'inhibiteurs du canal crac pour le traitement d'un accident vasculaire cerebral et d'une lesion cerebrale traumatique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA26473A1 (fr) * 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
CA2467870A1 (fr) * 2001-11-21 2003-06-05 Pharmacia & Upjohn Company Derives d'aryle-1,4-pyrazine substitues
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2005040151A1 (fr) * 2003-10-27 2005-05-06 Astellas Pharma Inc. Derives de pyrazine et utilisation pharmaceutique de ce derive
WO2006047504A1 (fr) * 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Amides aromatiques en tant qu’inhibiteurs de kinase c-fms

Also Published As

Publication number Publication date
CA2624621C (fr) 2010-11-30
ATE525372T1 (de) 2011-10-15
KR20080066073A (ko) 2008-07-15
AP2008004468A0 (en) 2008-06-30
US20070105872A1 (en) 2007-05-10
DOP2006000243A (es) 2007-05-31
ZA200803671B (en) 2009-03-25
GT200600475A (es) 2007-07-06
CN101356169A (zh) 2009-01-28
BRPI0618129A2 (pt) 2011-08-16
IL191059A0 (en) 2008-12-29
ECSP088412A (es) 2008-05-30
NO20082496L (no) 2008-07-24
UY29893A1 (es) 2007-06-29
WO2007052123A2 (fr) 2007-05-10
MA29926B1 (fr) 2008-11-03
PE20070715A1 (es) 2007-08-11
CA2624621A1 (fr) 2007-05-10
TW200804353A (en) 2008-01-16
WO2007052123A3 (fr) 2007-07-12
EP1945630B1 (fr) 2011-09-21
EP1945630A2 (fr) 2008-07-23
US7572797B2 (en) 2009-08-11
AR057855A1 (es) 2007-12-19
CR9954A (es) 2008-05-28
EA200801011A1 (ru) 2009-02-27
NL2000284A1 (nl) 2007-05-07
AU2006310215A1 (en) 2007-05-10
NL2000284C2 (nl) 2007-09-28
ES2371932T3 (es) 2012-01-11
JP2009514937A (ja) 2009-04-09

Similar Documents

Publication Publication Date Title
TNSN08196A1 (fr) Derives de pyrazine
TNSN08359A1 (fr) Derives d'amines
TNSN06051A1 (fr) Derives de piperazine pour le traitement d'infections par le hiv
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
TNSN06027A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
TNSN07022A1 (fr) Derives de pyridine
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
TNSN06386A1 (fr) Derives de tetraazabenzo [e] azulene et leurs analogues
TN2009000450A1 (fr) Derives de pyridine
MA30912B1 (fr) Nouveaux derives de phenylsulfamoyl-benzamide en tant qu'antagonistes de la bradykinine
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
BRPI0413973A (pt) compostos
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
MA30427B1 (fr) Derives bicycliques utilises comme inhibiteurs de cetp
MA32615B1 (fr) Inhibiteurs de cmet
MA31022B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees
GT200600327A (es) Ciclohexilaminoisoquinolona
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA30781B1 (fr) Inhibiteur de kinase
MA31021B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees en tant qu'inhibiteurs de la rho-kinase
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
MA29539B1 (fr) Procedes de production de derives phenoliques 4-biphenylylazetidin -2-one